Systemic lupus erythematosus

被引:0
作者
Kneitz, C
Goebeler, M
Tony, HP
机构
[1] Univ Wurzburg, Schwerpunkt Rheumatol & Klin Immunol, Med Poliklin, D-97070 Wurzburg, Germany
[2] Univ Wurzburg, Klin & Poliklin Haut & Geschlechtskrankheiten, D-97070 Wurzburg, Germany
来源
INTERNIST | 2003年 / 44卷 / 12期
关键词
systemic lupus erythematosus; autoantibodies; imunosuppressive therapy; neonatal lupus syndrom; antiphospholipid syndrom;
D O I
10.1007/s00108-003-1088-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic lupus erythematosus is a chronic inflammatory disease of unknown origin which can affect nearly every organ system. Young women are involved more frequently than men. SLE is characterized by periods of remissions and chronic or acute relapses. Diagnosis of SLE requires the presence of typical clinical and immunological criteria. Patients suffer from a wide array of symptoms and have a variable prognosis depending upon the severity and the type of organ involvement. Effective treatment is based on accurate determination of disease activity by clinical investigation, evaluation of characteristic autoantibodies like anti-DNA antibodies and determination of organ function with focus on renal and cerebral manifestations. The goal of treatment is stable remission which can be reached using immunosuppressive drugs like corticosteroids, antimalaries, azathioprine or cyclophosphamide. Longterm success requires avoidance of corticosteroid-induced toxicity, infections and accelerated atherosclerosis.
引用
收藏
页码:1557 / 1573
页数:17
相关论文
共 20 条
[1]   Antiphospholipid syndrome -: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients [J].
Cervera, R ;
Piette, JC ;
Font, J ;
Khamashta, MA ;
Cervera, R ;
Piette, JC ;
Font, J ;
Khamashta, MA ;
Shoenfeld, Y ;
Camps, MT ;
Jacobsen, S ;
Lakos, G ;
Tincani, A ;
Kontopoulou-Griva, I ;
Galeazzi, M ;
Meroni, PL ;
Derksen, RHWM ;
de Groot, PG ;
Gromnica-Ihle, E ;
Baleva, M ;
Mosca, M ;
Bombardieri, S ;
Houssiau, F ;
Gris, JC ;
Quéré, I ;
Hachulla, E ;
Vasconcelos, C ;
Roch, B ;
Fernández-Nebro, A ;
Boffa, MC ;
Hughes, GRV ;
Ingelmo, M .
ARTHRITIS AND RHEUMATISM, 2002, 46 (04) :1019-1027
[2]  
EDWORTHY SM, 2001, KELLEYS TXB RHEUMATO, P1113
[3]   Autoimmune diseases: genes, bugs and failed regulation [J].
Ermann, J ;
Fathman, CG .
NATURE IMMUNOLOGY, 2001, 2 (09) :759-761
[4]  
Esdaile JM, 1998, ARTHRITIS RHEUM, V41, pS139
[5]   The nature and outcome of infection in systemic lupus erythematosus [J].
Gladman, DD ;
Hussain, F ;
Ibañez, D ;
Urowitz, MB .
LUPUS, 2002, 11 (04) :234-239
[6]  
Gladman DD, 2000, J RHEUMATOL, V27, P373
[7]   Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].
Hochberg, MC .
ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1725-1725
[8]   Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents [J].
Karim, MY ;
Alba, P ;
Cuadrado, MJ ;
Abbs, IC ;
D'Cruz, DP ;
Khamashta, MA ;
Hughes, GRV .
RHEUMATOLOGY, 2002, 41 (08) :876-882
[9]   Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti-DNA antibody tests [J].
Kavanaugh, AF ;
Solomon, DH .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (05) :546-555
[10]   An open study of B lymphocyte depletion in systemic lupus erythematosus [J].
Leandro, MJ ;
Edwards, JC ;
Cambridge, G ;
Ehrenstein, MR ;
Isenberg, DA .
ARTHRITIS AND RHEUMATISM, 2002, 46 (10) :2673-2677